Industry
Biotechnology
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
April 05, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Insights
April 05, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
April 05, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
April 05, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 11:14 am
Portfolio Pulse from Happy Mohamed
March 13, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
March 04, 2024 | 9:32 pm
Portfolio Pulse from Benzinga Insights
December 11, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
November 03, 2023 | 12:14 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2023 | 12:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.